10x Genomics, Inc. - Common Stock (TXG)
Healthcare › Laboratory Analytical Instruments
Price History
Feb 9, 2026 — Apr 4, 2026Investment Snapshot
- P/B of 3.04 — trading above book value
- Piotroski F-Score 4/9 — moderate financial health
- Loss-making — negative ROE of -7.9%
- Revenue growing at 5% annually
10x Genomics, Inc. - Common Stock (TXG) is a Healthcare company operating in Laboratory Analytical Instruments, listed on the NASDAQ , with a market capitalisation of $2.4 billion . Key value metrics: P/B ratio 3.04, Piotroski F-Score 4 out of 9 (moderate financial health) .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
10x Genomics, Inc. - Common Stock — Fundamental Analysis Summary
On financial health, TXG shows a moderate Piotroski F-Score of 4/9, and negative return on equity of -7.9% (sector average: -19.8%), and manageable leverage with a debt-to-equity ratio of 0.31.
StockPik's composite Value Score for TXG is 49/100 — reflecting current market or financial concerns. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
TXG reports a high gross margin of 69.6% (sector average: 33.5%) and a negative operating margin of -13.2%.
TXG shows revenue growing at 5% year-over-year, with earnings growing at 76%.